People: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

66.10EUR
5:26am EDT
Price Change (% chg)

€-0.28 (-0.42%)
Prev Close
€66.38
Open
€66.45
Day's High
€66.57
Day's Low
€65.86
Volume
206,078
Avg. Vol
485,529
52-wk High
€67.78
52-wk Low
€55.20

Search Stocks

Kley, Karl-Ludwig 

Brief Biography

Dr. Karl-Ludwig Kley has been Chairman of the Executive Board and General Partner of Merck KGaA since April 27, 2007. He studied Law at Ludwig-Maximiliams-Universitaet Muenchen, from where he graduated with Bachelor degree, in 1979, and with Doctorate in Philosophy degree in 1986. He is Lawyer by profession. He has served as Member of the Supervisory Board of the Company from March 27, 2004 till June 30, 2006. He has served as Vice Chairman of the Executive Board of the Company from September 1, 2006 till April 27, 2007. He is responsible for Information Services, global Human Resources, Legal and Compliance, Patents, Auditing and Risk Management, Strategic Planning, In-house Consulting, Corporate Communications, Environment, Health and Safety. He is Member of the Supervisory Board of Bertelsmann AG and has been Vice Chairman of the Supervisory Board of BMW AG since May 18, 2010. He is Chairman of the Supervisory Board of 1. FC Koeln GmbH & Co KGaA. Prior to completing his studies, he completed an industrial business apprenticeship at Siemens AG. After completing his practical training as Lawyer in Hamburg and Johannesburg, from 1982 he worked in Corporate Finance and as Assistant to the Chairman of the Management Board at Bayer AG. After working abroad as Chief Financial Officer at Bayer in Japan, from 1987 to 1991, he held a number of senior management positions in the Pharmaceutical division in Sales and Marketing and, from 1994 to 1997, as Managing Director of the Italian subsidiary. Subsequently, he was in charge of Corporate Finance and Investor Relations at Bayer headquarters. In 1998, he joined the Executive Board of Lufthansa AG as Chief Financial Officer. He is also Member of the Presidential Council of the German Chemical Industry Association (VCI). He is also Member of the Executive Board and General Partner of E. Merck KG.

Basic Compensation

Total Annual Compensation, EUR Long-Term Incentive Plans, EUR All Other, EUR Fiscal Year Total, EUR
5,462,000 -- -- 7,311,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Rolf Krebs

95,026

Karl-Ludwig Kley

7,311,000

Heiner Wilhelm

72,019

Kai Beckmann

4,951,000

Constantin Fest

--

Stefan Oschmann

5,786,000
As Of 30 Dec 2013
Search Stocks